NCT02581124View on ClinicalTrials.gov

Study to Evaluate Effect of Lapatinib on Pharmacokinetics of JTZ-951 in Subjects With End-stage Renal Disease

PHASE1CompletedINTERVENTIONAL

Enrollment

10

Participants

Timeline

Start Date

October 31, 2015

Primary Completion Date

April 30, 2016

Study Completion Date

April 30, 2016

Conditions

Anemia of Chronic Kidney Disease

Interventions

DRUG

JTZ-951

DRUG

Lapatinib

Trial Locations (1)

Unknown

Minneapolis

Sponsors

Lead Sponsor

Akros Pharma Inc.

All Listed Sponsors

lead

Akros Pharma Inc.

INDUSTRY

NCT02581124 - Study to Evaluate Effect of Lapatinib on Pharmacokinetics of JTZ-951 in Subjects With End-stage Renal Disease | Biotech Hunter | Biotech Hunter